Literature DB >> 5696876

Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death.

I S Forrest, A G Bolt, M T Serra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5696876     DOI： 10.1016/0006-2952(68)90180-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  11 in total

Review 1.  Clinical use of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs.

Authors:  L E Hollister
Journal:  Drugs       Date:  1972       Impact factor: 9.546

2.  Legal-medical and toxicological evaluation of 18 lethal cases of poisoning by phenothiazine derivatives.

Authors:  W Nasilowski; H Sybirska; H Gajdzińska
Journal:  Z Rechtsmed       Date:  1974

3.  [Comparative enzyme studies in blood, erythrocytes and leukocytes of mentally retarded hospitalized patients].

Authors:  F Schweikhardt; J Hessing
Journal:  Humangenetik       Date:  1969

4.  Toxicological data on phenothiazine drugs in autopsy cases.

Authors:  R Bonnichsen; P Geertinger; A C Maehly
Journal:  Z Rechtsmed       Date:  1970

5.  Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.

Authors:  Iwona Karwaciak; Kaja Karaś; Anna Sałkowska; Joanna Pastwińska; Marcin Ratajewski
Journal:  Molecules       Date:  2022-06-07       Impact factor: 4.927

6.  Inhibitory effects of chlorpromazine on Candida species.

Authors:  N C Wood; K M Nugent
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Inhibition of human neutrophil chemotaxis in vitro by phenothiazines and related compounds.

Authors:  B Björkstén; P G Quie
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

8.  Repurposing chlorpromazine to treat COVID-19: The reCoVery study.

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-05-16       Impact factor: 1.291

9.  [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].

Authors:  M Plaze; D Attali; A-C Petit; M Blatzer; E Simon-Loriere; F Vinckier; A Cachia; F Chrétien; R Gaillard
Journal:  Encephale       Date:  2020-04-29       Impact factor: 1.291

10.  Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?

Authors:  B Nobile; M Durand; P Courtet; P Van de Perre; N Nagot; J P Molès; E Olié
Journal:  Schizophr Res       Date:  2020-07-25       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.